Valneva SE (VALN) Retained Earnings (2019 - 2026)
Valneva SE (VALN) posted quarterly Retained Earnings of $96.7 million for Q1 2026, up 11.2% year-on-year from $87.0 million in Q1 2025, and up 2.01% on a QoQ basis from $94.8 million in Q4 2025.
Valneva SE (VALN) Retained Earnings (2019 - 2026) Analysis & Trends
Valneva SE (VALN) has reported Retained Earnings for 8 consecutive years, with $96.7 million the latest figure, recorded in Q1 2026.
- Quarterly Retained Earnings rose 11.2% year-over-year to $96.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $96.7 million (up 11.2% YoY) and the FY2025 annual result came in at $94.8 million, up 115.1% from the prior year.
- Retained Earnings advanced to $96.7 million in Q1 2026 per VALN's latest filing, from $94.8 million in the prior quarter.
- Over the last five years, Retained Earnings for VALN reached as high as $96.7 million in Q1 2026 and fell as low as -$627.8 million in Q4 2024.
- A 5-year average of $34.9 million and a median of $74.1 million in 2023 frame the typical range for Retained Earnings.
- Annual changes were most pronounced in 2022 — Retained Earnings surged 123.66% — and 2024, when it sank 947.59%.
- Year by year, Retained Earnings stood at $62.9 million in 2022, then grew by 17.8% to $74.1 million in 2023, then slumped by 947.59% to -$627.8 million in 2024, then surged by 115.1% to $94.8 million in 2025, then increased by 2.01% to $96.7 million in 2026.
- According to Business Quant data, Retained Earnings over the past three periods registered $96.7 million, $94.8 million, and $92.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -527.87 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | -27.89 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 12.91 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 115.82 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 14.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 11.90 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -622,000.00 |
| 10 | Valneva SE | 803.90 Mn | 680.66 Mn | 5.38 Mn | 96.72 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 96.72 Mn |
| Dec 31, 2025 | 94.81 Mn |
| Sep 30, 2025 | 92.61 Mn |
| Jun 30, 2025 | 90.04 Mn |
| Mar 31, 2025 | 86.98 Mn |
| Dec 31, 2024 | -627.79 Mn |
| Sep 30, 2024 | 82.42 Mn |
| Jun 30, 2024 | 78.68 Mn |
| Mar 31, 2024 | 76.43 Mn |
| Dec 31, 2023 | 74.07 Mn |
| Sep 30, 2023 | 70.79 Mn |
| Jun 30, 2023 | 69.66 Mn |
| Mar 31, 2023 | 66.42 Mn |
| Dec 31, 2022 | 62.87 Mn |
| Sep 30, 2022 | 58.94 Mn |
| Jun 30, 2022 | 59.72 Mn |
| Mar 31, 2022 | 59.69 Mn |
| Dec 31, 2021 | -265.77 Mn |
| Jun 30, 2021 | 60.70 Mn |
| Dec 31, 2020 | 60.11 Mn |